BioCardia, Inc.
↗Sunnyvale, California, USA
BioCardia is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company integrates proprietary cell-based therapies with specialized delivery systems to treat unmet needs in heart failure and respiratory distress.
Their lead platform, CardiAMP, is a first-of-its-kind 'point-of-care' autologous cell therapy that processes a patient's own bone marrow to treat ischemic heart failure. The company also develops allogeneic (off-the-shelf) cell therapies and maintains a portfolio of steerable catheters and biotherapeutic delivery systems used by various partners in the biotech industry.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Regenerative Medicine / Cardiovascular Therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:< $1M
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$64.2M
Investors:Vanguard Group, Geode Capital Management, National Brands Inc.
STOCK
Exchange:NASDAQ
Ticker:BCDA
Market Cap:$12.1M
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (CardiAMP HF II)
Modalities:Cell therapy, Autologous stem cells, Allogeneic MSCs, Medical Devices (Catheters)
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:CART-Tech (Heart3D™ Fusion Imaging), AstraZeneca (Select device collaborations), Japan PMDA (Regulatory pathway alignment)
COMPETITION
Position:Niche Player
Competitors:Verve Therapeutics, Tenaya Therapeutics, Cardurion Pharmaceuticals, Elutia, Mesoblast
LEADERSHIP
Key Executives:
Peter Altman, Ph.D. - CEO
David McClung - CFO
Scientific Founders:Peter Altman, Simon Stertzer
Board Members:Andrew Scott Blank (Chairman), Marvin Slosman, Simon H. Stertzer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioCardia, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.